OBJECTIVE: Structural genetic variation, including copy-number variation (CNV), constitutes a substantial fraction of total genetic variability, and the importance of structural variants in modulating susceptibility is increasingly being recognized. CNV can change biological function and contribute to pathophysiological conditions of human disease. Its relationship with common, complex human disease in particular is not fully understood. Here, we searched the human genome to identify copy number variants that predispose to moya-moya type cerebrovascular disease. METHODS: We retrospectively analyzed patients who had unilateral or bilateral steno-occlusive lesions at the cerebral artery from March, 2007, to September, 2009. For the 20 subjects, including patients with moyamoya type pathologies and three normal healthy controls, we divided the subjects into 4 groups : typical moyamoya (n=6), unilateral moyamoya (n=9), progression unilateral to typical moyamoya (n=2) and non-moyamoya (n=3). Fragmented DNA was hybridized on Human610Quad v1.0 DNA analysis BeadChips (Illumina). Data analysis was performed with GenomeStudio v2009.1, Genotyping 1.1.9, cnvPartition_v2.3.4 software. Overall call rates were more than 99.8%. RESULTS: In total, 1258 CNVs were identified across the whole genome. The average number of CNV was 45.55 per subject (CNV region was 45.4). The gain/loss of CNV was 52/249, having 4.7 fold higher frequencies in loss calls. The total CNV size was 904,657,868, and average size was 993,038. The largest portion of CNVs (613 calls) were 1M-10M in length. Interestingly, significant association between unilateral moyamoya disease (MMD) and progression of unilateral to typical moyamoya was observed. CONCLUSION: Significant association between unilateral MMD and progression of unilateral to typical moyamoya was observed. The finding was confirmed again with clustering analysis. These data demonstrate that certain CNV associate with moyamoya-type cerebrovascular disease.
OBJECTIVE: Structural genetic variation, including copy-number variation (CNV), constitutes a substantial fraction of total genetic variability, and the importance of structural variants in modulating susceptibility is increasingly being recognized. CNV can change biological function and contribute to pathophysiological conditions of human disease. Its relationship with common, complex human disease in particular is not fully understood. Here, we searched the human genome to identify copy number variants that predispose to moya-moya type cerebrovascular disease. METHODS: We retrospectively analyzed patients who had unilateral or bilateral steno-occlusive lesions at the cerebral artery from March, 2007, to September, 2009. For the 20 subjects, including patients with moyamoya type pathologies and three normal healthy controls, we divided the subjects into 4 groups : typical moyamoya (n=6), unilateral moyamoya (n=9), progression unilateral to typical moyamoya (n=2) and non-moyamoya (n=3). Fragmented DNA was hybridized on Human610Quad v1.0 DNA analysis BeadChips (Illumina). Data analysis was performed with GenomeStudio v2009.1, Genotyping 1.1.9, cnvPartition_v2.3.4 software. Overall call rates were more than 99.8%. RESULTS: In total, 1258 CNVs were identified across the whole genome. The average number of CNV was 45.55 per subject (CNV region was 45.4). The gain/loss of CNV was 52/249, having 4.7 fold higher frequencies in loss calls. The total CNV size was 904,657,868, and average size was 993,038. The largest portion of CNVs (613 calls) were 1M-10M in length. Interestingly, significant association between unilateral moyamoya disease (MMD) and progression of unilateral to typical moyamoya was observed. CONCLUSION: Significant association between unilateral MMD and progression of unilateral to typical moyamoya was observed. The finding was confirmed again with clustering analysis. These data demonstrate that certain CNV associate with moyamoya-type cerebrovascular disease.
Entities:
Keywords:
Copy number variation (CNV); Moyamoya disease; Whole genome association study
Authors: Christopher L Hallemeier; Keith M Rich; Robert L Grubb; Michael R Chicoine; Christopher J Moran; DeWitte T Cross; Gregory J Zipfel; Ralph G Dacey; Colin P Derdeyn Journal: Stroke Date: 2006-04-27 Impact factor: 7.914
Authors: T Yamauchi; M Tada; K Houkin; T Tanaka; Y Nakamura; S Kuroda; H Abe; T Inoue; K Ikezaki; T Matsushima; M Fukui Journal: Stroke Date: 2000-04 Impact factor: 7.914
Authors: Jonathan Sebat; B Lakshmi; Jennifer Troge; Joan Alexander; Janet Young; Pär Lundin; Susanne Månér; Hillary Massa; Megan Walker; Maoyen Chi; Nicholas Navin; Robert Lucito; John Healy; James Hicks; Kenny Ye; Andrew Reiner; T Conrad Gilliam; Barbara Trask; Nick Patterson; Anders Zetterberg; Michael Wigler Journal: Science Date: 2004-07-23 Impact factor: 47.728
Authors: Y Mineharu; W Liu; K Inoue; N Matsuura; S Inoue; K Takenaka; H Ikeda; K Houkin; Y Takagi; K Kikuta; K Nozaki; N Hashimoto; A Koizumi Journal: Neurology Date: 2008-05-07 Impact factor: 9.910
Authors: Ynte M Ruigrok; Cisca Wijmenga; Gabriel J E Rinkel; Ruben van't Slot; Frank Baas; Marcel Wolfs; Andries Westerveld; Yvo B W E M Roos Journal: Stroke Date: 2008-02-28 Impact factor: 7.914
Authors: Tatiana Foroud; Laura Sauerbeck; Robert Brown; Craig Anderson; Daniel Woo; Dawn Kleindorfer; Matthew L Flaherty; Ranjan Deka; Richard Hornung; Irene Meissner; Joan E Bailey-Wilson; Guy Rouleau; E Sander Connolly; Dongbing Lai; Daniel L Koller; John Huston; Joseph P Broderick Journal: Stroke Date: 2008-03-06 Impact factor: 7.914